MedTrace Logo

A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.

NCT07619183 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-01

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.

Conditions

  • Lichen Simplex Chronicus

Interventions

DRUG

PG-033 tablets

Oral tablets (2mg, 10mg)

DRUG

PG-033 placebo comparator

Oral tablets (2mg, 10mg) (matching corresponding study medication)

Sponsors & Collaborators

  • Prime Gene Therapeutics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-04
Primary Completion
2026-09-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07619183 on ClinicalTrials.gov